Viemed Healthcare (NASDAQ:VMD) Lowered to "Buy" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Viemed Healthcare from “strong buy” to “buy,” while the broader analyst consensus remains “hold” after Freedom Capital also lowered its rating.
• Viemed reported quarterly EPS of $0.07, missing the $0.12 consensus estimate, although revenue of $78.1 million slightly exceeded expectations.
• The stock opened at $9.20, below its 50-day and 200-day moving averages; institutional investors own 74.24% of shares, while two insiders recently sold a combined 30,000 shares.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Saturday.

VMD has been the topic of a number of other research reports. Freedom Capital lowered shares of Viemed Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Viemed Healthcare from a "hold (c+)" rating to a "buy (b-)" rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Viemed Healthcare presently has a consensus rating of "Hold".

Viemed Healthcare Price Performance

Shares of NASDAQ:VMD opened at $9.20 on Friday. The stock has a market capitalization of $350.43 million, a P/E ratio of 25.56 and a beta of 1.10. The business has a 50-day moving average of $11.10 and a two-hundred day moving average of $9.81. Viemed Healthcare has a fifty-two week low of $6.05 and a fifty-two week high of $12.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.13 and a quick ratio of 1.02.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.05). Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. The company had revenue of $78.10 million for the quarter, compared to analyst estimates of $78.00 million. On average, equities research analysts predict that Viemed Healthcare will post 0.42 EPS for the current fiscal year.

Insider Activity at Viemed Healthcare

In other Viemed Healthcare news, Director Timothy Smokoff sold 20,000 shares of Viemed Healthcare stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $11.50, for a total value of $230,000.00. Following the transaction, the director directly owned 75,518 shares of the company's stock, valued at $868,457. The trade was a 20.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider William Frazier sold 10,000 shares of Viemed Healthcare stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $11.72, for a total value of $117,200.00. Following the completion of the transaction, the insider directly owned 73,214 shares in the company, valued at approximately $858,068.08. This represents a 12.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 20.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Viemed Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raffles Associates LP bought a new position in Viemed Healthcare during the second quarter worth $4,602,000. Hsbc Holdings PLC bought a new stake in Viemed Healthcare in the 2nd quarter valued at $434,000. Expect Equity LLC bought a new stake in Viemed Healthcare in the 2nd quarter valued at $2,425,000. PDT Partners LLC acquired a new stake in Viemed Healthcare in the 2nd quarter worth $268,000. Finally, Legal & General Group Plc acquired a new stake in Viemed Healthcare in the 2nd quarter worth $97,000. Institutional investors and hedge funds own 74.24% of the company's stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc NASDAQ: VMD is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source